-
1.发明授权
公开(公告)号：EP1740163B1
公开(公告)日：2010-07-14
申请号：EP05730867.8
申请日：2005-04-15
发明人： ENDRIKAT, Jan , DÜSTERBERG, Bernd
-
2.发明授权VERWENDUNG VON ESTRADIOLVALERAT ODER ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE DER DYSFUNKTIONELLEN UTERINEN BLUTUNG IN EINHEIT MIT EINER ORALEN KONTRAZEPTION 有权使用或雌激素雌二醇结合诺孕素FOR出血的功能失调性子宫出血单元口服避孕药口服治疗
公开(公告)号：EP1933843B1
公开(公告)日：2011-02-02
申请号：EP06806225.6
申请日：2006-10-12
发明人： ZEUN, Susan , BOUDES, Pol , ENDRIKAT, Jan , SECCI, Angelo , ZIMMERMANN, Holger
IPC分类号： A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The invention relates to the use of estradiol valerate or estradiol combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate or estradiol with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg or estradiol of less than 3mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate or estradiol of less than 2mg and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate or estradiol of less than 2mg and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate or estradiol of less than 2mg and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
-
3.发明公开VERWENDUNG VON ESTRADIOLVALERAT ODER ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE DER DYSFUNKTIONELLEN UTERINEN BLUTUNG IN EINHEIT MIT EINER ORALEN KONTRAZEPTION 有权使用或雌激素雌二醇结合诺孕素FOR出血的功能失调性子宫出血单元口服避孕药口服治疗
公开(公告)号：EP1933843A1
公开(公告)日：2008-06-25
申请号：EP06806225.6
申请日：2006-10-12
发明人： ZEUN, Susan , BOUDES, Pol , ENDRIKAT, Jan , SECCI, Angelo , ZIMMERMANN, Holger
IPC分类号： A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The invention relates to the use of estradiol valerate or estradiol combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate or estradiol with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg or estradiol of less than 3mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate or estradiol of less than 2mg and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate or estradiol of less than 2mg and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate or estradiol of less than 2mg and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
-
-
搜索结果
3 条记录 (耗时 0.009 秒)
